APRE Aprea Therapeutics Inc
8,819
$5.03
$0.0666
(1.31%)
| Watchers | 8,819 |
| 52-Wk Low | $2.78 |
| 52-Wk High | $8.85 |
| Market Cap | $27.31M |
| Volume | 16,256.00 |
| 52-Wk High | $8.85 |
| 52-Wk Low | $2.78 |
Aprea Therapeutics files to sell 4.39M shares of common stock for holdersThe Fly • about 2 months ago
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Share to Feed
Aprea Therapeutics (NASDAQ:APRE - Free Report) had its target price lifted by Wedbush from $9.00 to $11.00 in a research report sent to investors on Wednesday, Benzinga reports. Wedbush currently has...
Aprea Therapeutics, Inc. (NASDAQ:APRE Free Report) Equities researchers at Wedbush reduced their Q1 2024 EPS estimates for shares of Aprea Therapeutics in a research report issued on...
First-in-class macrocyclic ATR inhibitor, ATRN-119, on track to complete dose escalation and potentially generate human efficacy data in H2 2024 U.S. FDA cleared IND for APR-1051, a highly...
Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Aprea Therapeutics (APRE Research Report), with a price target of $20.00...
Aprea Therapeutics, Inc. (NASDAQ:APRE Get Free Report) Director Bernd R. Seizinger acquired 6,860 shares of the firms stock in a transaction on Wednesday, March 13th. The stock was...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
Financing led by Sphera Healthcare with participation from new and existing healthcare-focused institutional investors $16.0 million in upfront gross proceeds with the potential to receive up to an...
Company plans to initiate Phase 1 ACESOT-1051 (A Multi-Center Evaluation of WEE1 Inhibitor in Patients with Advanced Solid Tumors, APR-1051) clinical trial evaluating, highly selective, oral WEE1...